Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
MeSH terms: Waldenstrom Macroglobulinemia
Intervention: ABT199
Intervention description: Oral BCL-2 antagonist
Intervention MeSH terms: Venetoclax
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 33.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Waldenstrom Macroglobulinemia; WM

Summary:

      This research study is studying a targeted therapy as a possible treatment for relapsed or
      refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention
      ABT-199.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria
             for treatment using consensus panel criteria from the Second International Workshop on
             Waldenstrom's macroglobulinemia (Owen 2003; Kyle 2003).

          -  Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum
             IgM level of > 2 times the upper limit of normal of each institution is required.

          -  Have received at least one prior therapy for WM.

          -  Age ≥ 18 years.

          -  ECOG performance status <2 (see Appendix A).

          -  Participants must have normal organ and marrow function (growth factors cannot be
             given prophylactically to establish eligibility) as defined below:

               -  Absolute neutrophil count > 1,000/mm3

               -  Platelets > 50,000/mm3

               -  Hemoglobin > 8 g/dL

               -  Total bilirubin ≤ 1.5 mg/dL or < 2 mg/dL if attributable to hepatic infiltration
                  by neoplastic disease

               -  AST (SGOT) and ALT (SGPT) < 2.5X the institutional upper limit of normal

               -  Creatinine clearance ≥50 ml/min

          -  Not on any active therapy for other malignancies with the exception of topical
             therapies for basal cell or squamous cell cancers of the skin.

          -  Females of childbearing potential (FCBP) must agree to use two reliable forms of
             contraception simultaneously or have or will have complete abstinence from
             heterosexual intercourse during the following time periods related to this study: 1)
             while participating in the study; and 2) for at least 28 days after discontinuation
             from the study. Men must agree to use a latex condom during sexual contact with a FCBP
             even if they have had a successful vasectomy. FCBP must be referred to a qualified
             provider of contraceptive methods if needed.

          -  Able to adhere to the study visit schedule and other protocol requirements.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, uncontrolled intercurrent
             illness, or psychiatric illness/social condition that would prevent the participant
             from signing the informed consent form.

          -  Concurrent use of any other anti-cancer agents or treatments or any other study
             agents.

          -  Prior exposure to ABT-199 or BCL2 inhibitors.

          -  Prior or ongoing clinically significant illness, medical condition, surgical history,
             physical finding, ECG finding, or laboratory abnormality that, in the investigator's
             opinion, could affect the safety of the patient, including symptomatic hyperviscosity;
             alter the absorption, distribution, metabolism or excretion of ABT-199; or impair the
             assessment of study results.

          -  Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy.

          -  Known CNS lymphoma.

          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of screening.

          -  New York Heart Association classification III or IV heart failure.

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory
             bowel disease, or partial or complete bowel obstruction.

          -  Known history of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and/or
             Hepatitis C Virus (HCV) infection.

          -  Lactating or pregnant women.

          -  Inability to swallow tablets.

          -  History of non-compliance to medical regimens.

          -  Unwilling or unable to comply with the protocol.